Women, the menopause, hormone replacement therapy and coronary heart disease

Current Opinion in Cardiology

Volumn 30, Issue 4, 2015, Pages 432-438

  Whayne, Thomas F ^a   Mukherjee, Debabrata ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cardiovascular risk; Coronary heart disease; Hormone replacement; Inflammation; Menopause; Oestrogens; Thrombosis

Indexed keywords

HORMONE; LIPID; LIPOPROTEIN;

CARDIAC PATIENT; CORONARY RISK; FEMALE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOSIS; WOMEN'S HEALTH; CORONARY ARTERY DISEASE; HEALTH; INCIDENCE; PROCEDURES; RISK FACTOR;

CORONARY ARTERY DISEASE; FEMALE; GLOBAL HEALTH; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MENOPAUSE; RISK FACTORS;

EID: 84934935889     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000157     Document Type: Review

References (64)

1. Whayne T. Women and cardiovascular disease-prevention of heart disease. Int J Angiol 2006; 14:218-224.
2. Claassen M, Sybrandy KC, Appelman YE, Asselbergs FW. Gender gap in acute coronary heart disease: myth or reality? World J Cardiol 2012; 4:36-47.
3. Tsang W, Alter DA, Wijeysundera HC, et al. The impact of cardiovascular disease prevalence on women's enrollment in landmark randomized cardiovascular trials: a systematic review. J Gen Intern Med 2012; 27:93-98.
4. Melloni C, Berger JS, Wang TY, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 2010; 3:135-142.
5. Nguyen HL, Goldberg RJ, Gore JM, et al. Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry. Coron Artery Dis 2010; 21:336-344.
6. Vaccarino V, Krumholz HM, Yarzebski J, et al. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med 2001; 134:173-181.
7. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol 2009; 54:1561-1575.
8. Vavas E, Hong SN, Henry S, et al. Imaging tests, provocative tests, including exercise testing in women with suspected coronary artery disease. Curr Cardiovasc Risk Rep 2012; 6:469-478.
9. Niemela M, Kervinen K, Romppanen H, Vikman S. Coronary artery disease in women [in Finnish]. Duodecim 2009; 125:739-746.
10. Kang SJ, Ahn JM, Han S, et al. Sex differences in the visual-functional mismatch between coronary angiography or intravascular ultrasound versus fractional flow reserve. JACC Cardiovasc Interv 2013; 6:562-568.
11. Desai ND, Naylor CD, Kiss A, et al. Impact of patient and target-vessel characteristics on arterial and venous bypass graft patency: insight from a randomized trial. Circulation 2007; 115:684-691.
12. Albarran JW, Clarke BA, Crawford J. 'It was not chest pain really, I can't explain it!' An exploratory study on the nature of symptoms experienced by women during their myocardial infarction. J Clin Nurs 2007; 16:1292-1301.
13. Bozkurt B. Where do we currently stand with advice on hormone replacement therapy for women? Methodist Debakey Cardiovasc J 2010; 6:21-25.
14. Ostadal B, Ostadal P. Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications. Br J Pharmacol 2014; 171:541-554.
15. Ruiz AD, Daniels KR. The effectiveness of sublingual and topical compounded bioidentical hormone replacement therapy in postmenopausal women: an observational cohort study. Int J Pharm Compd 2014; 18:70-77.
16. Canonico M, Plu-Bureau G, O'Sullivan MJ, et al. Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials. Menopause 2014; 21:214-220.
17. Barbosa-Leiker C, Roper V, McPherson S, et al. Cross-sectional and longitudinal relationships between perceived stress and C-reactive protein in men and women. Stress Health 2014; 30:158-165.
18. Mascarenhas-Melo F, Marado D, Palavra F, et al. Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. Cardiovasc Diabetol 2013; 12:61.
19. Masszi G. Hypertension and menopause [in Hungarian]. Orv Hetil 2002; 143:2821-2828.
20. Dull P. Hormone replacement therapy. Prim Care 2006; 33:953-963.
21. Rowe TC. Hormone replacement therapy: what is available now, and what is on the horizon. BC Med J 2001; 43:521-526.
22. Whelan AM, Jurgens TM, Trinacty M. Defining bioidentical hormones for menopause-related symptoms. Pharm Pract (Granada) 2011; 9:16-22.
23. Manson JE. Current recommendations: what is the clinician to do? Fertil Steril 2014; 101:916-921.
24. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465-1477.
25. Bassuk SS, Manson JE. Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification. Clin Chem 2014; 60:68-77.
26. Carpenter JS, Byrne MM, Studts JL. Factors related to menopausal symptom management decisions. Maturitas 2011; 70:10-15.
27. Newton KM, Reed SD, Nekhyludov L, et al. Factors associated with successful discontinuation of hormone therapy. J Womens Health (Larchmt) 2014; 23:382-388.
28. Manson JE. The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy. Metabolism 2013; 62 (Suppl 1): S15-S19.
29. Canonico M. Hormone therapy and hemostasis among postmenopausal women: a review. Menopause 2014; 21:753-762.
30. Hulka BS. Links between hormone replacement therapy and neoplasia. Fertil Steril 1994; 62:168S-175S.
31. O'Donnell E, De Souza MJ. The cardiovascular effects of chronic hypoestrogenism in amenorrhoeic athletes: a critical review. Sports Med 2004; 34:601-627.
32. Joswig M, Hach-Wunderle V, von Holst T, Nawroth PP. Postmenopausal hormone replacement therapy and the vascular wall: epidemiology and clinical studies. Vasa 2000; 29:243-251.
33. Villablanca AC, Jayachandran M, Banka C. Atherosclerosis and sex hormones: current concepts. Clin Sci (Lond) 2010; 119:493-513.
34. Tasci T, Sukur YE, Ozmen B, et al. Effects of transdermal and oral hormone replacement therapies on monocyte chemoattractant protein-1 levels: a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 176:50-54.
35. Lahm T, Crisostomo PR, Markel TA, et al. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit Care Med 2008; 36:2174-2183.
36. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166:357-365.
37. Prelevic GM, Kwong P, Byrne DJ, et al. A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002; 77:945-951.
38. Onat A, Can G. Enhanced proinflammatory state and autoimmune activation: a breakthrough to understanding chronic diseases. Curr Pharm Des 2014; 20:575-584.
39. Spoletini I, Vitale C, Rosano GM. Biomarkers for predicting postmenopausal coronary heart disease. Biomark Med 2011; 5:485-495.
40. Hamirani YS, Pandey S, Rivera JJ, et al. Markers of inflammation and coronary artery calcification: a systematic review. Atherosclerosis 2008; 201:1-7.
41. Krintus M, Kozinski M, Kubica J, Sypniewska G. Critical appraisal of inflammatory markers in cardiovascular risk stratification. Crit Rev Clin Lab Sci 2014; 51:263-279.
42. Soares FH, de Sousa MB. Different types of physical activity on inflammatory biomarkers in women with or without metabolic disorders: a systematic review. Women Health 2013; 53:298-316.
43. Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes 2009; 2:41-48.
44. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
45. Singh S, Singh H, Loftus EV Jr, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12:382-393.
46. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96:4211-4218.
47. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
48. Wenger N. Coronary heart disease in women: a 'new' problem. Hosp Pract 1992; 27:59-74.
49. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010; 121:1069-1077.
50. Bukkapatnam RN, Gabler NB, Lewis WR. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol 2010; 13:84-90.
51. Truong QA, Murphy SA, McCabe CH, et al. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes 2011; 4:328-336.
52. Mosca L. Sex, statins, and statistics. Lancet [serial on the Internet] 2015. http://www. ncbi. nlm. nih. gov/pubmed/25595662. [Accessed 13 January 2015] The 2015 meta-analysis by Mosca [52], even though specifically on statins and not HRT, is of major importance in further clarifying the use of statins in the female patient and in adding an emphasis to cardiovascular risk management in women.
53. van der Schouw YT, van der Graaf Y, Steyerberg EW, et al. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996; 347:714-718.
54. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999; 159:1061-1066.
55. Wellons M, Ouyang P, Schreiner PJ, et al. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause 2012; 19:1081-1087.
56. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13:265-279.
57. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000; 132:689-696.
58. Simon T, Beau Yon de Jonage-Canonico M, Oger E, et al. Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism. J Thromb Haemost 2006; 4:71-76.
59. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22:201-210.
60. Cho L, Mukherjee D. Hormone replacement therapy and secondary cardiovascular prevention: a meta-analysis of randomized trials. Cardiology 2005; 104:143-147.
61. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
62. Speroff L. The heart and estrogen/progestin replacement study (HERS). Maturitas 1998; 31:9-14.
63. US Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U. S. Preventive Services Task Force. Ann Intern Med 2005; 142:855-860.
64. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003; 107:149-158.